Why we do what we do.
Care Oncology has a mission. Our mission is to act in our patients’ best interests, by helping them to live longer and healthier lives, and to do so without fear. People with cancer are hurting and fearful and in pain. We know and understand this. We bring a humility, a humanity and a willingness to learn to our work as we believe that nobody should be left behind and denied care.
The world of cancer research is often focused on the “moonshot” – the search for a cure, which is invariably hugely expensive. We believe that at the same time, we should be looking for “groundshots” too – doing whatever we can, with what we have, where we are now.
The Old and the New
Our core belief is that many old medicines are potentially useful in new ways. Some of them can and do help in cancer, and we know that modern economic incentives and industrial imperatives make it supremely difficult for the effort needed to enable their use in cancer to happen.
Modern medicine has moved forward tremendously, and there have been many exciting breakthroughs in cancer therapy but there is little doubt that many of the new approaches can be helped by the old medicines too. Patients should get the best of the old and the new.
One of Care Oncology’s foundational values is that we are EVIDENCE-DRIVEN. We will not recommend or prescribe anything that does not have sufficient evidence to show safety and efficacy. Any drugs we prescribe will be safe for you when given:
- Singly (on their own)
- In combination (with each other)
- Alongside Standard of Care (the modern medicines and treatments that your oncologist will prescribe).
We looked at a very large number of medicines, and we narrowed it right down to a specific handful of drugs that are known to be safe, and where the evidence showed that clinical benefit was likely.
Our clinical study
Going further, we have committed to gathering the data on the outcomes achieved by our patients in our real-world clinical setting, and publishing that in peer-reviewed journals from time to time. It took a huge amount of work to design a new study called an “Interventional Service Evaluation” and to obtain regulatory and ethical approval in the UK. This approval would not have been forthcoming unless we could satisfy regulators about the safety of our approach.
Our patients often ask us about other off-label drugs that they have heard about, where there is a suggestion that these drugs might help their cancer. Our position is that generally there is not enough evidence available as to the safety and efficacy of these drugs for us to be able to recommend or prescribe them, particularly in the context of a cancer patient undergoing standard of care treatments. In medicine, the combining of drugs is a very complex matter and one must consider all of the different treatments being given. Safety cannot be considered for a drug in isolation – the context really matters.
We chose our combination of medicines because of the wealth of data on them in cancer and the known safety profile of these medicines separately, together and with standard of care. This level of data and safety information does not exist for other products – particularly when given in combination with your standard of care.
Our drugs are generally accepted to be safe. However, they are still powerful in their effects. Cancer patients are put through a lot and adding further medicines to their bodies needs care, and it is absolutely imperative that they are monitored carefully. This is not a simple or trivial matter, nor is it an afterthought. It is central to what we do. We have many years of experience in thousands of patients and there are no short-cuts. Our doctors are trained in how to monitor you and they make adjustments over time to your treatment.
We believe that it would be unethical for us to treat you without ongoing monitoring, and we believe that doctors who do not have the specialist training in metabolic oncology should not attempt to provide this treatment.
We are aware that some clinicians are copying our patented, proprietary protocol and charging patients to write the prescriptions. This is possible because we made an early decision to be open about our protocol and what it contained, in order to achieve our mission and get these drugs to patients who need them. In some cases, we have heard that the clinicians involved do not even review the patient’s medical records or the standard of care that is being given concurrently, nor do they understand the nature of the patient’s disease.
The doctors who do this are diminishing and undermining our mission in several ways, (a) they are not in a position to monitor and support the patients as well as we can, risking their patients’ health (b) they are risking the mission by preventing us from collecting the data on patient outcomes, which is so badly needed, (c) if patients suffer through the lack of appropriate support, the case for repurposing old medicines will be irreparably damaged.
Join our mission
Join us. Be a part of this mission. Stay with us and allow us to do our job which is to keep you safe and also to learn from you, so that others might benefit too.
From our many years of speaking with patients and getting to know them personally, we know that they all want to make things better for others in the future – everybody wants to see cancer defeated. To everyone we treat, we say the same thing:
We have fought for many years to change the paradigm of cancer treatment, to combine the best of the old and the new, to use groundshots while we wait for the moonshots, and not to leave millions of people behind.
Join us. Stay with us.